Tranexamic acid has received FDA approval for several indications related to bleeding control.
What is tranexamic acid FDA approved for?
The U.S. Food and Drug Administration (FDA) has approved tranexamic acid for:
* Treatment of Hemorrhagic Diathesis: This includes its use in patients with conditions like congenital or acquired defibrinogenation, dysfibrinogenemia, acute and chronic liver diseases, consumptive coagulopathy (e.g., disseminated intravascular coagulation, DIC), and certain other coagulation disorders [1].
* Prevention and Treatment of Bleeding: It is used to prevent or treat bleeding associated with extracorporeal circulation, such as during open-heart surgery. It is also approved for the treatment of heavy menstrual bleeding [2].
How does tranexamic acid work?
Tranexamic acid is an antifibrinolytic agent. It works by inhibiting the activation of plasminogen to plasmin. Plasmin is an enzyme that breaks down fibrin, a protein crucial for blood clot formation. By preventing excessive fibrin breakdown, tranexamic acid helps stabilize blood clots and reduce bleeding [1][2].
When was tranexamic acid first approved by the FDA?
The FDA approved tranexamic acid in 1980 [2].
Are there other uses for tranexamic acid?
While not its primary FDA-approved indications, tranexamic acid is used off-label in various medical settings. This includes topical application for nosebleeds and in some surgical procedures to minimize blood loss. Research is ongoing into its potential benefits for other conditions, such as stroke [3].
What are the side effects of tranexamic acid?
Common side effects associated with tranexamic acid can include gastrointestinal issues like nausea, vomiting, and diarrhea. Allergic reactions are also possible. More serious side effects, though rare, can include vision changes, dizziness, and blood clots [1][2]. Patients should discuss any potential risks with their healthcare provider.
Can tranexamic acid be used during pregnancy?
The use of tranexamic acid during pregnancy should be carefully considered and discussed with a healthcare professional, as its safety profile in pregnant individuals is not fully established.
What is the difference between tranexamic acid and aminocaproic acid?
Both tranexamic acid and aminocaproic acid are antifibrinolytic agents that work by inhibiting plasmin. They are structurally similar and have comparable efficacy in many clinical situations. However, tranexamic acid is generally considered to be more potent than aminocaproic acid. The choice between them often depends on the specific clinical scenario, physician preference, and availability [1].
Who manufactures tranexamic acid?
Tranexamic acid is available from multiple pharmaceutical manufacturers. Specific brand names and manufacturers can vary by region and availability.
What is the patent status of tranexamic acid?
Tranexamic acid is an older drug, and its original patents have long expired. This means generic versions are widely available [4].
Sources:
1. DrugPatentWatch.com
2. U.S. Food & Drug Administration. (n.d.). Prescribing Information for Tranexamic Acid.
3. DrugPatentWatch.com
4. DrugPatentWatch.com